Publications by authors named "G BROGLIO"
Background: Biologic therapies are associated with increased infection risk among elderly patients with inflammatory bowel disease (IBD). However, there are few data on the safety and effectiveness of ustekinumab compared with anti-tumor necrosis factor (anti-TNF) agents in the elderly.
Methods: The study sought to compare the safety and effectiveness of ustekinumab and anti-TNF agents in elderly Crohn's disease (CD) patients.
Article Synopsis
- - Despite advances in treating inflammatory bowel disease (IBD), tissue fibrosis commonly occurs, often leading to the need for surgery due to strictures caused by excessive extracellular matrix deposition.
- - Fibrogenesis is a natural response to chronic inflammation, but its mechanisms remain partly unclear, with ongoing inflammation in the mucosa being a primary trigger influenced by myofibroblasts, fibroblasts, immune cells, and growth factors.
- - Currently, there are no therapies targeting fibrosis directly; thus, managing inflammation is crucial to preventing fibrogenesis, as discussed in the review of mechanisms, diagnosis, and potential drug targets for fibrosis.
Background: Pregnant women with inflammatory bowel disease (IBD) continue thiopurines to maintain remission. Other studies have reported intrahepatic cholestasis of pregnancy (ICP) in IBD pregnancies exposed to thiopurines. We aimed to investigate whether thiopurines are associated with an increased risk of ICP.
View Article and Find Full Text PDFThe intestinal mucosa represents the most extensive human barrier having a defense function against microbial and food antigens. This barrier is represented externally by a mucus layer, consisting mainly of mucins, antimicrobial peptides, and secretory immunoglobulin A (sIgA), which serves as the first interaction with the intestinal microbiota. Below is placed the epithelial monolayer, comprising enterocytes and specialized cells, such as goblet cells, Paneth cells, enterochromaffin cells, and others, each with a specific protective, endocrine, or immune function.
View Article and Find Full Text PDFBackground: We aim to compare the real-life direct and indirect costs of switching patients from intravenous to subcutaneous (SC) CT-P13, an infliximab biosimilar, in a tertiary UK Inflammatory Bowel Disease (IBD) centre.
Methods: All adult patients with IBD on standard dosing CT-P13 (5 mg/kg 8 weekly) were eligible to switch. Of 169 patients eligible to switch to SC CT-P13, 98 (58%) switched within 3 months and one moved out of area.